cofactor for the shuttle mechanism whereby long-chain fatty acids are transformed into acylcarnitine derivatives (acylcarnitines whose acyl moiety consists of 10 or more carbon atoms) and may be transported into mitochondria for energy liberation via /3-oxidation.' Camitine palnitoyltransferase (CPT) is the mandatory enzyme for this shuttle mechanism.' In addition, carnitine and the enzyme carnitine acetyltransferase (CAT)' are involved in the following reaction:
Acetylcoenzyme A + carnitine = acetylcarnitine + coenzyme A This reaction modulates the intracellular concentration of coenzyme A (CoA) and acetylCoA. Through this reaction, carnitine produces free CoA for other metabolic reactions and reduces the ratio of acetylCoA to CoA. This reduction stimulates the activity of pyruvate dehydrogenase and thus enhances the oxidative use of glucose. [2] [3] [4] As a consequence of these mechanisms of action, an adequate carnitine availability and the efficiency of the carnitine-linked system are important factors for muscle metabolism, especially in providing efficient regulation of the energy flow from the different oxidative sources. Patients with primary carnitine deficiency are characterized by cardiomyopathy and progressive muscle weakness, which can be partially reversed by carnitine supplementation.56 One of the possible consequences of ischemia is secondary carnitine deficiency. A decrease in myocardial carnitine content has been observed in experimental animals as a result of acute and chronic coronary ischemia7, 8 and in humans after acute myocardial infarction. 9 Replacement of carnitine to the ischemic myocar- Dowex 2-X8 200-400 mesh was added, and the mixture was vortexed and chilled in an ice bath for 10 minutes. Then, the mixture was centrifuged, and the final surnatant containing labeled acetylcarnitine was counted in a }3-scintillation counter. CPT activity was determined by the isotope exchange method described by Solberg21 as modified by Trevisan et al. 22 Citrate synthase was measured according to the method of Srere.23 NADH dehydrogenase was assayed as described by Singer.24 Creatine phosphokinase (CPK) was determined according to the method of Hess et al-25
In four additional patients, carnitine, acylcarnitines, and enzyme activities were measured in the ischemic muscles 2 days after intravenous administration of L-propionylcarnitine (1.5 g as a single bolus followed by an infusion of 1 mg/kg/min for 30 minutes. The characteristics of these patients (Table  2) were similar to those of the untreated patients.
Biopsy specimens were obtained under local anesthesia from the normoperfused muscles of four healthy male subjects (mean age, 61.4+4.0 years) who received L-propionylcarnitine at the dosage indicated above.
Informed consent was obtained from all patients and control subjects before the study began.
The data of the present study were compared with those obtained from the muscles of 35 normal subjects previously studied in our laboratory. Group Muscle Levels of Camitine and Its Fractions Muscular levels of total carnitine observed in patients with peripheral vascular disease and in normal subjects are shown in Figure 1 . Compared with the normoperfused muscles of control subjects, the ischemic muscles of untreated patients showed a significant reduction in total carnitine, from 20.9 ±5.2 to 11.6+6.2 nmol/mg noncollagen protein (p<0.01). This reduction can be attributed to a significantly lower content in free carnitine and acylcarnitines (Table 3) . On the contrary, the content of carnitine and its fractions in the ischemic muscles of patients treated with L-propionylcarnitine did not differ from those of controls. Furthermore, total and free carnitine levels were significantly higher than those in untreated patients (Table 3) .
As shown in Table 3 , L-propionylcarnitine did not modify the muscle levels of carnitine and its fractions in the four normal subjects treated before biopsy. This demonstrates that at the dose used in the present study, L-propionylcarnitine is taken up only by carnitine-deficient muscles.
Enzyme Activities
The activities of CAT and CPT in the skeletal muscles are shown in Figure 2 . A significant reduction in CAT acylcarnitines, yet an increased amount of carnitine is required to buffer the acylCoA pool and a secondary carnitine deficiency takes place under the impaired metabolic conditions.33 Accordingly, it is possible that in patients with peripheral vascular disease, the increasing severity of the ischemic process parallels a progressive increase in the production of acylcarnitines, leading to a depletion of carnitine from the ischemic muscle. The present study demonstrates that patients of stage III or IV of Fontaine's classification show a marked reduction in the muscle content of carnitine. Loss of carnitine through functionally impaired cell membranes may contribute to the extent of this phenomenon.
Our patients also exhibited a decreased activity of CAT. This, in addition to a decreased availability of carnitine, is responsible for the reduced formation of short-chain acylcarnitines and a consequent noxious accumulation of acylCoA esters in the ischemic muscles. The possibility that CAT activity is decreased as a consequence of cell necrosis appears to be ruled out by the finding that the activities of the other enzymes measured in the ischemic muscles were within the normal range.
Administration of L-carnitine to patients with peripheral vascular disease of stage II of Fontaine's classification significantly increases muscle total carnitine levels and improves maximal walking ability. '5 In the present study, we used L-propionylcarnitine, a naturally occurring derivative of carnitine, because it has been postulated that the propionyl structure of this compound accelerates carnitine entry into myocytes. 34 Our results demonstrate that L-propionylcarnitine administration to patients with severe peripheral vascular disease restores normal levels of carnitine and its esters in the ischemic muscles. Treatment significantly increased total and free carnitine compared with values observed in the untreated group. Short-and long-chain acylcarnitines also increased twofold, although this increase was not significant. These findings indicate that part of the administered L-propionylcarnitine (a short-chain acyl derivative) was taken up by the ischemic muscles and that a consistent portion was transformed into free carnitine. In effect, L-propionylcarnitine exhibits a very high affinity for CAT35 and thus is readily converted into propionylCoA and free carnitine.
PropionylCoA does not affect 3-oxidation, but it may be converted into succinylCoA36 and thus may contribute to the beneficial action of carnitine by increasing the flux in the Kreb's cycle with an anaplerotic mechanism. Furthermore, the linear correlation observed between total carnitine levels and citrate synthase activity suggests that L-propionylcarnitine increases the functional activity of this matrix enzyme, probably through acylCoA removal. 37 It is interesting that administration of L-propionylcarnitine to normal subjects did not modify the muscle content of carnitine and its esters. This indicates that at the dosage used in the present study, L-propionylcarnitine is taken up only by muscles showing a condition of carnitine insufficiency.
Conclusions
Carnitine is a crucial factor for energy production in the ischemic skeletal muscle.15 Therefore, a decrease in both carnitine levels and the activity of CAT may play an important role in the pathophysiology of peripheral vascular disease. The feasibility of carnitine replacement in the ischemic muscles by L-propionylcarnitine provides the basis for clinical trials aimed at assessing the efficacy of this carnitine ester in the treatment of peripheral vascular disease.
